Treating histologically mild chronic hepatitis C: Monotherapy, combination therapy, or tincture of time?

Annals of Internal Medicine

Volumn 129, Issue 4, 1998, Pages 323-326

  Levine, Robert A ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b University Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERLEUKIN 10; NONSTEROID ANTIINFLAMMATORY AGENT; RIBAVIRIN; THYMOSIN ALPHA1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CONSERVATIVE TREATMENT; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VIREMIA;

EID: 0031852042     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-4-199808150-00010     Document Type: Review

References (26)

1. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-6
2. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med. 1997;127:875-81.
3. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon α in the treatment of chronic hepatitis C. Gastroenterology. 1996;11:1307-12.
4. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerbörg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83-7.
5. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, et al. Retreatment of relapse after interferon therapy for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone [Abstract], Hepatology. 1997;26:249A.
6. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 1998;27:1136-43.
7. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26(Suppl 1):2S-10S.
8. Gavier B, Martinez-González MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology. 1997;113:1647-53.
9. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127: 855-65.
10. Koff RS. Interferon-α for chronic hepatitis C: reducing the uncertainties [Editorial]. Ann Intern Med. 1997;127:918-20.
11. Levine RA, Ranek L. Asymptomatic chronic hepatitis. Correlation between isolated serum transaminase abnormality and liver biopsy. Gastroenterology. 1970;58:371-8.
12. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24: 289-93.
13. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-32.
14. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-40.
15. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 1997;26(3 Suppl 1):133S-6S.
16. Silverman AL, Piquette DL, Filipiak CL, Neill JS, Bayati N, Gordan SC. Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels. Am J Gastroenterol. 1997;92:1793-5.
17. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 1998;27:868-72.
18. Pawlotsky JM. Chronic hepatitis C virus infection with repeatedly normal aminotransferase levels: disease or not disease? [Editorial] Am J Gastroenterol. 1997;92:1775-7.
19. Suzuki H, Iino S, Omata M, Kumada H, Hino K. Efficacy of consensus interferon (CIFN) against chronic HCV patients with high viral titer. The Consensus Interferon Clinical Study Group [Abstract]. Hepatology. 1997; 26:422A.
20. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis Hepatology. 1997;25:759-68.
21. DiBisceglie A, Bonkovsky H, Krawitt E, Grace N. Killenberg P, Hunt C, et al. Iron reduction therapy in chronic hepatitis C [Abstract]. Hepatology. 1997;26:214A.
22. Pardo M, Castillo I, Oliva H, Fernández-Flores A, Bárcena R, de Peuter MA, et al. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology. 1997;26:1318-21.
23. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology. 1997;25:1527-38.
24. von Weizsäcker F, Wieland S, Köck J, Offensperger WB, Offensperger S, Moradpour D, et al. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology. 1997;26:251-5.
25. Wu CH, Wu GY. Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines. Gastroenterology. 1998;114:1304-12.
26. Berg T, Kaul T, Heuft HG, Naumann U, Lobeck H, Hopf U. Long-term efficacy of interferon in chronic hepatitis C [Abstract]. Hepatology 1997;26: 423A.